Chronic Dietary Supplementation of Branched-Chain Amino Acids Does Not Attenuate Muscle

Total Page:16

File Type:pdf, Size:1020Kb

Chronic Dietary Supplementation of Branched-Chain Amino Acids Does Not Attenuate Muscle Chronic Dietary Supplementation of Branched-Chain Amino Acids Does Not Attenuate Muscle Torque Loss in a Mouse Model of Duchenne Muscular Dystrophy Justin E. Sperringer Dissertation submitted to the faculty of the Virginia Polytechnic Institute and State University in partial fulfillment of the requirements for the Doctor of Philosophy in Human Nutrition, Foods, & Exercise Advisory Committee: Committee Chair – Susan Hutson Committee Co-Chair – Matthew Hulver Robert Grange Dongmin Liu Samer El-Kadi August 2nd, 2019 Blacksburg, VA Keywords: Duchenne Muscular Dystrophy; dystrophin; dystrophin glycoprotein complex; amino acids; branched-chain amino acids; leucine; isoleucine; valine; mTOR; skeletal muscle; muscle function Chronic Dietary Supplementation of Branched-Chain Amino Acids Does Not Attenuate Muscle Torque Loss in a Mouse Model of Duchenne Muscular Dystrophy Justin E. Sperringer Academic Abstract Duchenne Muscular Dystrophy (DMD) is an X-linked recessive, progressive muscle-wasting disease characterized by mutations in the dystrophin gene. Duchenne muscular dystrophy is the most common and most severe form of inherited muscle diseases, with an incidence of 1 in 3,500 male births1,2. Mutations in the dystrophin gene result in non-functional dystrophin or the complete absence of the protein dystrophin, resulting in necrosis and fibrosis in the muscle, loss of ambulation, cardiomyopathies, inadequate or failure of respiratory function, and decreased lifespan. Although there has been little research for effective nutritional strategies, dietary intervention may be effective as an adjuvant treatment. In this study, wild type (WT) and mdx animals were provided either a control or elevated branched chain amino acid (BCAA) diet nocturnally for 25 weeks to determine if the elevated BCAAs would attenuate muscle torque loss. Twenty-five weeks of chronic, elevated BCAA supplementation had no impact on muscle function measures. Interestingly, mdx and WT animals had the same torque responses in the low stimulation frequencies (1 Hz – 30 Hz) compared to higher stimulation frequencies. Tetanus was reached at a much lower stimulation frequency in mdx animals compared to WT animals (100 Hz vs +150 Hz). The mdx mouse consistently had more cage activity in the light cycle X- and Y-planes. Interestingly, animals on the BCAA diet increased X-, Y-, and Z-plane activity in the dark cycles at four weeks while animals on the control diet more Z-plane activity at 25 weeks, although not significant. All three BCAAs were elevated in the plasma at 25 weeks, although only Leu was significantly elevated. The BCAAs had no effect on. The diaphragm and skeletal muscle masses were larger in mdx animals, and WT animals had a significantly larger epididymal fat pad. The active state of BCKDC determined by phosphorylation of the E1α enzyme was greater in WT animals in white skeletal muscle, but not red skeletal muscle. Protein synthesis effectors of the mTORC1 signaling pathway and autophagy markers were similar among groups. Wild type animals had increased mTORC1 effectors and animals on the BCAA diet had decreased autophagy markers, although not significant. Although BCAAs did not affect muscle function, fibrosis, or protein synthesis effectors, this study illustrates the functionality of mdx muscles over time. It would be interesting to see how the different muscle fiber types are affected by DMD, noting the differences between the diaphragm, heart, red muscle, and white muscle fibrosis markers. Although there was no increase in mTORC1 effectors with an elevated BCAA diet, it would be interesting to determine muscle protein synthesis, myofibrillar protein synthesis, and total protein turnover in the mdx mouse with an elevated BCAA diet, although the dietary intervention started when mice arrived at 4 weeks of age, earlier intervention may be beneficial early in the disease process. Chronic Dietary Supplementation of Branched-Chain Amino Acids Does Not Attenuate Muscle Torque Loss in a Mouse Model of Duchenne Muscular Dystrophy Justin E. Sperringer General Audience Abstract Duchenne Muscular Dystrophy (DMD) is an X-linked recessive, progressive muscle-wasting disease characterized by mutations in the dystrophin gene. Duchenne muscular dystrophy is the most common and most severe form of inherited muscle diseases, with an incidence of 1 in 3,500 male births1,2. Mutations in the dystrophin gene result in non-functional dystrophin or the complete absence of the protein dystrophin, resulting in necrosis and fibrosis in the muscle, loss of movement and walking ability, cardiomyopathies, inadequate or failure of respiratory function, and decreased lifespan. Although there has been little research for effective nutritional strategies, dietary intervention may be effective as an adjuvant treatment and palliative care. The branched chain amino acids (BCAAs) are known to directly stimulate muscle protein synthesis by direct activation of the mechanistic target of rapamycin complex 1 (mTORC1). This study aimed to illustrate the differences between diseased and healthy mice and determine if BCAAs can reduce muscle torque loss. Twenty-five weeks of chronic, elevated BCAA supplementation had no impact on muscle function measures. Interestingly, mdx and WT animals had the same torque responses in the low stimulation frequencies (1 Hz – 30 Hz) compared to higher stimulation frequencies. Tetanus was reached at a much lower stimulation frequency in mdx animals compared to WT animals (100 Hz vs +150 Hz). The mdx mouse consistently had more cage activity in the light cycle X- and Y-planes. Interestingly, animals on the BCAA diet increased X-, Y-, and Z-plane activity in the dark cycles at four weeks while animals on the control diet more Z-plane activity at 25 weeks, although not significant. All three BCAAs were elevated in the plasma at 25 weeks, although only Leu was significantly elevated. The BCAAs had no effect on. The diaphragm and skeletal muscle masses were larger in mdx animals, and WT animals had a significantly larger epididymal fat pad. The active state of BCKDC determined by phosphorylation of the E1α enzyme was greater in WT animals in white skeletal muscle, but not red skeletal muscle. Protein synthesis effectors of the mTORC1 signaling pathway and autophagy markers were similar among groups. Wild type animals had increased mTORC1 effectors and animals on the BCAA diet had decreased autophagy markers, although not significant. Although BCAAs did not affect muscle function, fibrosis, or protein synthesis effectors, this study illustrates the functionality of mdx muscles over time. It would be interesting to see how the different muscle fiber types are affected by DMD, noting the differences between the diaphragm, heart, red muscle, and white muscle fibrosis markers. Although there was no increase in mTORC1 effectors with an elevated BCAA diet, it would be interesting to determine muscle protein synthesis, myofibrillar protein synthesis, and total protein turnover in the mdx mouse with an elevated BCAA diet, although the dietary intervention started when mice arrived at 4 weeks of age, earlier intervention may be beneficial early in the disease process. Table of Contents Academic abstract…………………………………………………………………….………………….. i General audience abstract……………………………………………..……….……………………….. iii Table of contents…………………………………………………………….………………………....… v Dedication………………………………………………………………………….………………...... viii List of abbreviations………………………………………………………………..………….……..… ix List of figures……………………………………………….………………………………...…….…. xiii CHAPTER ONE Introduction………………………………………………………………………………….… 1 Hypotheses…………………………………………………………………………………….. 2 CHAPTER TWO Literature review…………………………………………………………………....................... 3 Clinical description…………………………………………………….……………………….. 3 Diagnosis………………………………………………………………………………………... 3 Dystrophin…………………………………………………………..…………………………... 4 Dystrophin glycoprotein complex……………………………………………..………………... 8 Utrophin……………………………………………………………………………..…. 8 Dystrophin-dystroglycan subcomplex………………….……………………………… 9 Sarcoglycan-sarcospan subcomplex……………………………..……………………... 9 Dystrophin-syntrophin subcomplex………………………………………………….… 9 Signaling associated with the dystrophin glycoprotein complex……………………………..... 10 vi Molecular mechanism of Duchenne muscular dystrophy……………………………………… 12 Myopathies associated with the dystrophin glycoprotein complex…………………………..… 12 Current treatments………………………………………………………………………..……. 15 Pharmacological treatments………………………………………………………...… 18 Genetic strategies……………………………………………………………………... 20 Cellular strategies…………………………………………………………………….. 22 Genome editing……………………………………………………………………….. 22 Nutritional strategies to promote muscle protein synthesis………………………….… 24 mTORC1……………………………………………………………………………………..... 27 Nutritional strategies as an adjuvant therapy………………………………………………..… 28 CHAPTER THREE Chronic Dietary Supplementation of Branched-Chain Amino Acids Does Not Attenuate Muscle Function and Strength Loss in a Mouse Model of Duchenne Muscular Dystrophy……………………………... 30 Methods………………………………………………………………………………………... 30 Animals……………………………………………………………………………….. 30 Diets…………………………………………………………………………………... 30 Body composition…………………………………………………………………….. 33 Metabolic & activity monitoring……………………………..……………………..… 33 in vivo muscle function………………………………………….…………………….. 34 Western blots………………………………………………………………………..… 34 Plasma and tissue amino acids………………………………………………………... 36 Hydroxyproline……………………………………………………….…………….… 37 Statistics……………………………………………………………………………....
Recommended publications
  • Opportunities and Challenges for Antisense Oligonucleotide Therapies
    Received: 10 January 2020 Revised: 23 April 2020 Accepted: 8 May 2020 DOI: 10.1002/jimd.12251 REVIEW ARTICLE Opportunities and challenges for antisense oligonucleotide therapies Elsa C. Kuijper1 | Atze J. Bergsma2,3 | W.W.M. Pim Pijnappel2,3 | Annemieke Aartsma-Rus1 1Department of Human Genetics, Leiden University Medical Center, Leiden, The Abstract Netherlands Antisense oligonucleotide (AON) therapies involve short strands of modi- 2Department of Pediatrics, Center for fied nucleotides that target RNA in a sequence-specific manner, inducing Lysosomal and Metabolic Diseases, targeted protein knockdown or restoration. Currently, 10 AON therapies Erasmus Medical Center, Rotterdam, The Netherlands have been approved in the United States and Europe. Nucleotides are chem- 3Department of Clinical Genetics, Center ically modified to protect AONs from degradation, enhance bioavailability for Lysosomal and Metabolic Diseases, and increase RNA affinity. Whereas single stranded AONs can efficiently Erasmus Medical Center, Rotterdam, The Netherlands be delivered systemically, delivery of double stranded AONs requires capsulation in lipid nanoparticles or binding to a conjugate as the uptake Correspondence enhancing backbone is hidden in this conformation. With improved chem- Annemieke Aartsma-Rus, LUMC Postzone S4-P, Albinusdreef 2, 2333 ZA istry, delivery vehicles and conjugates, doses can be lowered, thereby reduc- Leiden, The Netherlands. ing the risk and occurrence of side effects. AONs can be used to knockdown Email: [email protected] or restore levels of protein. Knockdown can be achieved by single stranded Communicating Editor: Carla E. Hollak or double stranded AONs binding the RNA transcript and activating RNaseH-mediated and RISC-mediated degradation respectively. Transcript binding by AONs can also prevent translation, hence reducing protein levels.
    [Show full text]
  • Viltepso™ (Viltolarsen) – Value & Balance Exchange Medical Benefit
    UnitedHealthcare® Value & Balance Exchange Medical Benefit Drug Policy Viltepso™ (Viltolarsen) Policy Number: IEXD0095.03 Effective Date: August 1, 2021 Instructions for Use Table of Contents Page Related Policies Applicable States ........................................................................... 1 None Coverage Rationale ....................................................................... 1 Applicable Codes .......................................................................... 2 Background ................................................................................... 2 Benefit Considerations .................................................................. 3 Clinical Evidence ........................................................................... 3 U.S. Food and Drug Administration ............................................. 4 References ..................................................................................... 5 Policy History/Revision Information ............................................. 5 Instructions for Use ....................................................................... 5 Applicable States This Medical Benefit Drug Policy only applies to the states of Arizona, Maryland, North Carolina, Oklahoma, Tennessee, Virginia, and Washington. Coverage Rationale See Benefit Considerations Viltepso (viltolarsen) may be covered for the treatment of Duchenne muscular dystrophy (DMD) in patients who meet all of the following criteria: For initial therapy, all of the following: o Diagnosis of
    [Show full text]
  • 5.01.570 Pharmacologic Treatment of Duchenne Muscular Dystrophy
    PHARMACY / MEDICAL POLICY – 5.01.570 Pharmacologic Treatment of Duchenne Muscular Dystrophy Effective Date: Aug. 6, 2021 RELATED MEDICAL POLICIES: Last Revised: June 11, 2021 11.01.523 Site of Service: Infusion Drugs and Biologic Agents Replaces: N/A Select a hyperlink below to be directed to that section. POLICY CRITERIA | DOCUMENTATION REQUIREMENTS | CODING RELATED INFORMATION | EVIDENCE REVIEW | REFERENCES | HISTORY ∞ Clicking this icon returns you to the hyperlinks menu above. Introduction Amondys 45® (casimersen), Exondys 51® (eteplirsen), Viltepso™ (vitolarsen), and Vyondys 53® (golodirsen) are new drugs used for Duchenne Muscular Dystrophy (DMD), which is a rare genetic disorder characterized by progressive muscle degeneration and weakness. It is caused by an absence of a functional dystrophin, which is a protein that helps keep muscle cells intact. Dystrophin gene is thought to be defective when its structure contains one or more exon deletions due to a genetic mutation. This disease primarily affects boys. Symptom onset is usually in early childhood, between ages 3 and 5. Muscle weakness can begin as early as age 3, first affecting the muscles of the hips, pelvic area, thighs and shoulders, and later the skeletal (voluntary) muscles in the arms, legs, and trunk. By the early teens, the heart and respiratory muscles also get affected, often requiring the use of assistive devices. Tests used to diagnose DMD vary from a blood test (measuring creatine kinase) to the muscle biopsy (measuring dystrophin protein levels), to the genetic testing (looking for the defective dystrophin gene). Standard of therapy is aimed at slowing the loss of muscle strength to maximize the quality of life, and involves physical therapy and medications, such as steroids: prednisone and deflazacort.
    [Show full text]
  • Oregon Drug Use Review / Pharmacy & Therapeutics Committee
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301‐1079 Phone 503‐947‐5220 | Fax 503‐947‐1119 Oregon Drug Use Review / Pharmacy & Therapeutics Committee Thursday, August 5th, 2021 1:00 ‐ 5:00 PM Remote Meeting via Zoom Platform MEETING AGENDA NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410‐121‐0030 & 410‐121‐0040 in accordance with Oregon Revised Statute 183.333. I. CALL TO ORDER 1:00 PM A. Roll Call & Introductions R. Citron (OSU) B. Approval of Agenda R. Citron (OSU) C. Conflict of Interest Declaration R. Citron (OSU) D. Approval of Minutes R. Citron (OSU) E. Department Update T. Douglass (OHA) F. Legislative Update T. Douglass (OHA) 1:20 PM II. CONSENT AGENDA TOPICS S. Ramirez (Chair) A. CMS Annual Report B. Quarterly Utilization Reports C. Oncology Prior Authorization Updates 1. Public Comment III. DUR ACTIVITIES 1:25 PM A. ProDUR Report L. Starkweather (Gainwell) B. RetroDUR Report D. Engen (OSU) C. Oregon State Drug Review K. Sentena (OSU) 1. Antidepressant Review 2. Bipolar Disorder: Resources for Primary Care Providers IV. PREFERRED DRUG LIST NEW BUSINESS 1:45 PM A.
    [Show full text]
  • WO 2019/067979 Al 04 April 2019 (04.04.2019) W 1P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2019/067979 Al 04 April 2019 (04.04.2019) W 1P O PCT (51) International Patent Classification: B 14202, Cambridge, Massachusetts 02139 (US). NI¬ A61K 31/166 (2006.01) A61K 45/06 (2006.01) CHOLS, Andrew J.; c/o CATABASIS PHARMACEUTI¬ A61K 31/7125 (2006.01) A61P 21/00 (2006.01) CALS, INC., One Kendall Square, Suite B 14202, Cam¬ bridge, Massachusetts 02139 (US). (21) International Application Number: PCT/US20 18/053 543 (74) Agent: ROSE GILLENTINE, Marsha et al; STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C, 1100 New York (22) International Filing Date: Avenue, NW, Washington, District of Columbia 20005 28 September 2018 (28.09.2018) (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (30) Priority Data: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/565,016 28 September 2017 (28.09.2017) US DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/737,750 27 September 2018 (27.09.2018) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (71) Applicants: SAREPTA THERAPEUTICS, INC. KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, [US/US]; 215 First Street, Cambridge, Massachusetts MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 02142 (US).
    [Show full text]
  • Medications for Duchenne Muscular Dystrophy SERVICE: Casimersen
    MEDICAL COVERAGE POLICY SERVICE: Medications for Duchenne Muscular Dystrophy Policy Number: 280 Effective Date: 05/01/2021 Last Review: 03/25/2021 Next Review Date: 03/25/2022 Important note: Unless otherwise indicated, this policy will apply to all lines of business. Even though this policy may indicate that a particular service or supply may be considered medically necessary and thus covered, this conclusion is not based upon the terms of your particular benefit plan. Each benefit plan contains its own specific provisions for coverage and exclusions. Not all benefits that are determined to be medically necessary will be covered benefits under the terms of your benefit plan. You need to consult the Evidence of Coverage (EOC) or Summary Plan Description (SPD) to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and your plan of benefits, the provisions of your benefits plan will govern. However, applicable state mandates will take precedence with respect to fully insured plans and self-funded non-ERISA (e.g., government, school boards, church) plans. Unless otherwise specifically excluded, Federal mandates will apply to all plans. With respect to Medicare-linked plan members, this policy will apply unless there are Medicare policies that provide differing coverage rules, in which case Medicare coverage rules supersede guidelines in this policy. Medicare-linked plan policies will only apply to benefits paid for under Medicare rules, and not to any other health benefit plan benefits. CMS's Coverage Issues Manual can be found on the CMS website.
    [Show full text]
  • Peptides and Oligonucleotides) Harvest
    pharmaceuticals Review 2020 FDA TIDES (Peptides and Oligonucleotides) Harvest Othman Al Musaimi 1,† , Danah Al Shaer 2,† , Fernando Albericio 1,3,4,* and Beatriz G. de la Torre 2,* 1 School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa; [email protected] 2 KRISP, School of Laboratory of Medicine and Medical Science, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa; [email protected] 3 Networking Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain 4 Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), 08034 Barcelona, Spain * Correspondence: [email protected] (F.A.); [email protected] (B.G.d.l.T.); Tel.: +27-614-009-144 (F.A.); +27-614-047-528 (B.G.d.l.T.) † These authors contributed equally to this work. Abstract: 2020 has been an extremely difficult and challenging year as a result of the coronavirus disease 2019 (COVID-19) pandemic and one in which most efforts have been channeled into tackling the global health crisis. The US Food and Drug Administration (FDA) has approved 53 new drug entities, six of which fall in the peptides and oligonucleotides (TIDES) category. The number of authorizations for these kinds of drugs has been similar to that of previous years, thereby reflecting the consolidation of the TIDES market. Here, the TIDES approved in 2020 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects. Keywords: belantamab mafodotin-blmf; 64Cu-DOTATATE; drugs; FDA; 68Ga-PSMA-11; lumasiran; setmelanotide; oligonucleotides; peptides; viltolarsen Citation: Al Musaimi, O.; Al Shaer, D.; Albericio, F.; de la Torre, B.G.
    [Show full text]
  • 212154Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212154Orig1s000 RISK ASSESSMENT AND RISK MITIGATION REVIEW(S) Division of Risk Management (DRISK) Office of Medication Error Prevention and Risk Management (OMEPRM) Office of Surveillance and Epidemiology (OSE) Center for Drug Evaluation and Research (CDER) Application Type NDA Application Number 212154 PDUFA Goal Date August 12, 2020 OSE RCM # 2019-2248 Reviewer Names Jacqueline Sheppard, PharmD Lindsey Crist, PharmD, BCPS Team Leader Laura Zendel, PharmD Acting Division Director Doris Auth, PharmD Review Completion Date August 4, 2020 Subject Evaluation of Need for a REMS Established Name Viltolarsen Trade Name Viltepso Name of Applicant Nippon Shinyaku Co, Ltd. Therapeutic Class Antisense oligonucleotide Formulation Solution for injection Dosing Regimen 80 mg/kg administered by intravenous infusion once weekly 1 Reference ID: 4651290 Table of Contents EXECUTIVE SUMMARY...................................................................................................................................................3 1 Introduction..............................................................................................................................................................3 2 Background...............................................................................................................................................................3 2.1 Product Information .....................................................................................................................................3
    [Show full text]
  • Viltepso® (Viltolarsen) – Commercial Medical Benefit Drug Policyopens
    UnitedHealthcare® Commercial Medical Benefit Drug Policy Viltepso® (Viltolarsen) Policy Number: 2021D0095D Effective Date: August 1, 2021 Instructions for Use Table of Contents Page Community Plan Policy Coverage Rationale ....................................................................... 1 • Viltepso® (Viltolarsen) Applicable Codes .......................................................................... 2 Background.................................................................................... 2 Benefit Considerations .................................................................. 4 Clinical Evidence ........................................................................... 4 U.S. Food and Drug Administration ............................................. 4 References ..................................................................................... 5 Policy History/Revision Information ............................................. 5 Instructions for Use ....................................................................... 6 Coverage Rationale See Benefit Considerations Viltepso (viltolarsen) may be covered for the treatment of Duchenne muscular dystrophy (DMD) in patients who meet all of the following criteria: For initial therapy, all of the following: o Diagnosis of Duchenne muscular dystrophy by, or in consultation with, a neurologist with expertise in the diagnosis of DMD; and o Submission of medical records (e.g., chart notes, laboratory values) confirming the mutation of the DMD gene is amenable to exon 53
    [Show full text]
  • 213026Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 213026Orig1s000 SUMMARY REVIEW Summary Memorandum Date Febrnarv 18, 2021 Teresa Buracchio, M.D. Deputy Director, Division of Neurology 1 From Eric Ba.stings, M.D. Deputy Director, Office of Neuroscience Subject Sunnmuy Memorandum NDA/BLA # and Supplement# 213026 Applicant Sarepta Date of Submission June 25, 2020 PDUFA Goal Date Febrnary 25, 2021 Proprietary Name Amondys 45 Established or Proper Name Casimersen Dosa2eForm Intravenous solution Treatment ofDuchenne muscular dystrophy (DMD) in Applicant Proposed Indication/ I Cb> "~f patients who have a confomed Population mutation of the DMD gene that is amenable to exon 45 skipping. Applicant Proposed Dosing 30 mg/week Re2imen Re2ulatorv Action Approval Treatment ofDuchenne muscular dystrophy (DMD) in I (b)~l patie. nts who have a confomed Approved Indication/ Population mutation of the DMD gene that is amenable to exon 45 skipping. Approved Dosin2 Re2imen 30 mg/week NDA 213026- Su mmary Memorandum; February 18, 2021 1 Reference ID 4751615 1. Benefit-Risk Assessment Benefit-Risk Integrated Assessment Duchenne muscular dystrophy (DMD) is a rare progressive X‐linked neuromuscular disorder caused by mutations in the dystrophin gene. Lack of dystrophin results in degeneration of muscle fibers, inflammation, and ultimately replacement of muscle by fibrotic and adipose tissue. The disease causes progressive and profound muscle weakness and degeneration. Muscle weakness typically begins between ages 3 to 5 years, with loss of ambulation usually occurring by 12 years of age. Death typically occurs before age 30 years, generally from respiratory and/or cardiac muscle involvement. The disease prevalence is estimated to be 1.4 per 10,000 males ages 5 to 24 years.
    [Show full text]
  • Therapeutic Strategies for Duchenne Muscular Dystrophy: an Update
    G C A T T A C G G C A T genes Review Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update Chengmei Sun 1,2, Luoan Shen 1, Zheng Zhang 1 and Xin Xie 1,2,* 1 Zhejiang University-University of Edinburgh Institute, School of Medicine, Zhejiang University, Haining 314400, China; [email protected] (C.S.); [email protected] (L.S.); [email protected] (Z.Z.) 2 Department of Medical Oncology, the Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310009, China * Correspondence: [email protected]; Tel.: +86-0571-87572326 Received: 30 May 2020; Accepted: 21 July 2020; Published: 23 July 2020 Abstract: Neuromuscular disorders encompass a heterogeneous group of conditions that impair the function of muscles, motor neurons, peripheral nerves, and neuromuscular junctions. Being the most common and most severe type of muscular dystrophy, Duchenne muscular dystrophy (DMD), is caused by mutations in the X-linked dystrophin gene. Loss of dystrophin protein leads to recurrent myofiber damage, chronic inflammation, progressive fibrosis, and dysfunction of muscle stem cells. Over the last few years, there has been considerable development of diagnosis and therapeutics for DMD, but current treatments do not cure the disease. Here, we review the current status of DMD pathogenesis and therapy, focusing on mutational spectrum, diagnosis tools, clinical trials, and therapeutic approaches including dystrophin restoration, gene therapy, and myogenic cell transplantation. Furthermore, we present the clinical potential of advanced strategies combining gene editing, cell-based therapy with tissue engineering for the treatment of muscular dystrophy.
    [Show full text]
  • CCS NL 02-0321 Treatment Of
    State of California—Health and Human Services Agency Department of Health Care Services WILL LIGHTBOURNE GAVIN NEWSOM DIRECTOR GOVERNOR DATE: May 25, 2021 N.L.: 02-0321 Supersedes: N.L.: 11-1120, 05-0618 Index: Benefits TO: All California Children Services Program County Administrators, Medical Consultants, Genetically Handicapped Persons Program Staff and Integrated Systems of Care Division Staff SUBJECT: Antisense Oligonucleotide Treatment of Duchenne Muscular Dystrophy I. PURPOSE This Numbered Letter (N.L.) establishes California Children’s Services (CCS) and Genetically Handicapped Persons Program (GHPP) Program policy regarding the authorization of antisense oligonucleotide treatments for Duchenne muscular dystrophy (DMD).1 The CCS Program publishes this N.L. under the program’s authority to authorize services that are medically necessary to treat CCS-eligible conditions.2,3,4 II. BACKGROUND DMD is a genetic disorder causing progressive muscle deterioration and weakness . The absence or deficient levels of dystrophin protein, which maintains intact muscle cells, causes muscle deterioration and weakness. DMD primarily affects a patient’s skeleton, diaphragm, and heart muscle. DMD occurs in about 1 in 3,600 male infants worldwide. DMD rarely occurs in females. Symptoms typically appear in the first three years of life and progressively worsen over time. Affected individuals gradually lose their ability to perform daily activities and are usually wheelchair bound by adolescence and ventilator dependent by their 20s or 30s. Clients with gene variants amenable to skipping of certain exons can produce functional, although truncated, dystrophin protein in the presence of eteplirsen, golodirsen, or viltolarsen, respectively. Eteplirsen (Exondys 51™) is an antisense oligonucleotide that targets mutations amenable to exon 51 skipping, was the first treatment for DMD approved in the Integrated Systems of Care Division 1501 Capitol Avenue, MS 4502 P.O.
    [Show full text]